文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

梗阻性肥厚型心肌病室间隔消融与心肌切除术的生存比较

Survival Following Alcohol Septal Ablation or Septal Myectomy for Patients With Obstructive Hypertrophic Cardiomyopathy.
PubMed 文献 · J Am Coll Cardiol · 2022-01-01

本研究在3个肥厚型心肌病专科中心评估了3859例接受酒精室间隔消融(ASA)或室间隔心肌切除术的梗阻性肥厚型心肌病患者的长期死亡率。中位随访6.4年,ASA组10年全因死亡率为26.1%,心肌切除组为8.2%;校正年龄、性别和合并症后,ASA仍与更高的全因死亡风险独立相关(HR 1.68;95%CI 1.29-2.19;P<0.001)。

要点

  • ASA组患者年龄更大、室间隔更薄且合并症更多。
  • 中位随访6.4年,ASA组10年全因死亡率26.1%,心肌切除组8.2%。
  • 校正混杂因素后,ASA与更高全因死亡风险独立相关(HR 1.68)。

核心结论

  • 在梗阻性肥厚型心肌病患者中,与室间隔心肌切除术相比,ASA与更高的长期全因死亡率相关。
  • 该生存影响独立于其他已知因素,但可能受未测量的患者特征混杂影响。

研究设计与样本

  • 研究纳入3个肥厚型心肌病专科中心接受ASA或室间隔心肌切除术的3859例患者。
  • ASA组585例(15.2%),室间隔心肌切除组3274例(84.8%)。
  • 主要终点为全因死亡率,中位随访6.4年(IQR 3.6-10.2年)。

主要发现

  • ASA组中位年龄63.0岁(IQR 52.7-72.8),心肌切除组53.7岁(IQR 44.9-62.8),P<0.001。
  • ASA组室间隔厚度中位19.0 mm(IQR 17.0-22.0),心肌切除组20.0 mm(IQR 17.0-23.0),P=0.007。
  • ASA组早期死亡4例(0.7%),心肌切除组9例(0.3%)。
  • 10年全因死亡率ASA组26.1%,心肌切除组8.2%。
  • 校正年龄、性别和合并症后,ASA组死亡风险仍更高(HR 1.68;95%CI 1.29-2.19;P<0.001)。

临床怎么用

  • 在梗阻性肥厚型心肌病需室间隔减容治疗的患者中,选择室间隔心肌切除术可能较ASA获得更好的长期生存。
  • 决策时应综合考虑患者年龄、合并症及室间隔厚度等特征。

局限性

  • 研究为观察性设计,ASA组与心肌切除组基线特征差异显著,可能存在未测量的混杂因素。
  • 结论可能受未测量的患者特征影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is little information regarding long-term mortality comparing the 2 most common procedures for septal reduction for obstructive hypertrophic cardiomyopathy (HCM), alcohol septal ablation (ASA), and septal myectomy. OBJECTIVES: This study sought to compare the long-term mortality of patients with obstructive HCM following septal myectomy or ASA. METHODS: We evaluated outcomes of 3,859 patients who underwent ASA or septal myectomy in 3 specialized HCM centers. All-cause mortality was the primary endpoint of the study. RESULTS: In the study cohort, 585 (15.2%) patients underwent ASA, and 3,274 (84.8%) underwent septal myectomy. Patients undergoing ASA were significantly older (median age: 63.0 years [IQR: 52.7-72.8 years] vs 53.7 years [IQR: 44.9-62.8 years]; P < 0.001) and had smaller septal thickness (19.0 mm [IQR: 17.0-22.0 mm] vs 20.0 mm [IQR: 17.0-23.0 mm]; P = 0.007). Patients undergoing ASA also had more comorbidities, including renal failure, diabetes, hypertension, and coronary artery disease. There were 4 (0.7%) early deaths in the ASA group and 9 (0.3%) in the myectomy group. Over a median follow-up of 6.4 years (IQR: 3.6-10.2 years), the 10-year all-cause mortality rate was 26.1% in the ASA group and 8.2% in the myectomy group. After adjustment for age, sex, and comorbidities, the mortality remained greater in patients having septal reduction by ASA (HR: 1.68; 95% CI: 1.29-2.19; P < 0.001). CONCLUSIONS: In patients with obstructive hypertrophic cardiomyopathy, ASA is associated with increased long-term all-cause mortality compared with septal myectomy. This impact on survival is independent of other known factors but may be influenced by unmeasured confounding patient characteristics.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Cui H, Schaff HV, Wang S, et al. Survival Following Alcohol Septal Ablation or Septal Myectomy for Patients With Obstructive Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2022. PMID: 35483751. doi:10.1016/j.jacc.2022.02.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。